Quarterly guidance

Quarterly guidance
No specific quarterly guidance figures were given for the next quarter.

Annual guidance

Organic sales growth
Expected to grow at the upper end of the 5% to 7% target in 2027.
Adjusted operating income margin
Expected to reach 20% in 2027.
Adjusted EPS growth
Expected to meet or exceed the long-term target of 12% to 15% in 2027.

Outlook

Commodity cost inflation
Commodity costs are expected to remain high, with continued pricing execution and disciplined supply chain management used to offset the impact.
Global High-Tech ambition
Global High-Tech is targeted to grow more than 25% annually, reach $4 billion in sales by 2030, and deliver a 25% operating income margin.
Life Sciences margins
Life Sciences is approaching $1 billion in sales with operating income margins on a trajectory to expand to 30% over the next few years.
Volume and pricing trends
Underlying volume growth is expected around 1% to 2%, with pricing running higher in the near term to manage ongoing cost pressures.